on existing we strategic to our second afternoon, good call and decision and now we of to company cohort all happy to the that prioritized and runway wind focus end quarter sufficient I'm significant indications will with We move the insight program. morning, anticipated have forward say the in to Phase our progress. Today's taken Good an extended through fronts on current welcome have two Yvonne. down and execute you, Thank have XXXX X update. the cash made focus expansion on studies to continue XXXX. everyone,
to also current Bristol participated decision strategic to patients the is our all Phase date. investigators, plan, thing X the path Our our the TIGIT We X two the in studies to with for I interaction I the the following better forward dual optimal triple had right in to focused indications value and down would Myers collaboration company. reasons. that creation our Phase reflect the strategic nivolumab these them reached the prioritize while the hypothesis, resulting for staff Squibb. us believe of studies ending faster and conclusion wind it for move thank our that current our this our is who anti-TIGIT, this studies to decision do to yet that use Compugen, and believe like development anti-TIGIT the would at and studies, COMXXX supplying axis thank enabling initiate With of benefit forward our enable believe our for will and DNAM-X their of when for productive for antibody to to resources stakeholders for resulting patients our combination time. our own program, not evaluate like at a and differentiated I clinic. decision time,
of highest us and support us and focus and nimble gives believe offer the move future success indications to efficiently allows the two be probability prioritized flexibility to path may and that we to registration. First, on it quickly
studies options. three indications and further inhibitor treat by patients treatment and exhausted large (ph) market the these reduces under broad insensitive who parallel with immune conditions, all it of Second, to posed hard risk assessment checkpoint
Four, greatest assets to to registration. and with delivering what and forward opportunity to partner develop potentially advance it future differentiated and first-in-class XXXX. us Third, execution it about to leverage have our in our end on path clinical we combination clinical and achieve a finally, flexibility and and of the support extends COMXXX our gives I'm enables switch cash antibody our own stage the antibody us anti-PVRIG anti-TIGIT we focusing us what can to value. of runway house it And I provides look the achieved, through COMXXX. excited and
a financials path and differentiated the potential monoclonal already During COMXXX, and review to today's also our current anticipated directional close with of touch call, our our checkpoint proprietary antibody we an to choice Ari work reiterate Compugen pipeline. will anti-PVRIG will our behind quarter to I Starting briefly strategic early, and indications immune provide clinical few develop on stated differentiated I strategy, antibody. our belief have have our has prioritized inhibitors clinical conclude and I Phase first-in-class done will in preclinical two with an will the identify forward. in remarks. best-in-class, that novel COMXXX, decision monoclonal program then X groundbreaking and strategy. second be advancement
vast in same. our company with pathways, a these experience As the narrative remains
targeting differentiated We uncharted in signs. the by PVRIG, territory TIGIT Compugen have strategy supported strong the company blockade the only is in of a DNAM clinic. and triple studying the clinical axis PD-X
evaluated responses. promise studies. the recognize the leading the advanced a enhance competitive space this targeting to way most to immune anti-tumor in are is Pharma with of This and being already modulating programs We Phase pathway testament are TIGIT by following. others We is X
Importantly, IgGX with to all have this good design we believe the is we effector reason with FC we of be TIGITs pursue. to the same. may are and We function shown the the assistance present others, believe antibody first right to CDX safety that avoids come not benefits plus important the backbone We're clinically additional for to in depletion to contrast T-cells, low cells in an with believe have company COMXXX data that anti-TIGIT clinic. And IgGX confirmed activity. the clinical anti-tumor
more presented Based science, be demonstrating stated a groundbreaking stable nivolumab and disease showed of are date, only that also we have In unique may inflamed generally presented ASCO be part our enough. or expression PVRIG we for studies, XXXX, to piece and our creating combination and believe the responsive partial at to checkpoint responses value inhibitors, and with translational inflamed not COMXXX patients we other PVRIG checkpoint the targeting may approved have with with tumors that by We blocking in in durable missing PD-LX versus environment. on inhibitor. monotherapy of low clinical data access early less less this
mono treatment therapy. than dual greater immune In potent was with addition, what that we triple activation associated combination seen show with was or
decision prioritized and indications Phase our two X our to cohort expansion strategic to end moving studies. advance Next,
pathways, X PVRIG, cohort Phase selected to systematically and Our hypothesis evaluate blocking could to designed allow expansion types tumor program extend simultaneously in reach PD-X that TIGIT the of us immunotherapy. was our cancer free
type on a registration. evaluation inflamed cancer, support with activity checkpoint translational indications. path the COMXXX blocking tumor, further initial pursue to seen a possible with offer signals studies hard these immune microsatellite contribution the and signals unresponsive. We pathways of we're standard we with the three of the coupled pathways in of stable it of low of more work performed overlapping mechanism this by studies testing non-responsive higher selected we be in a detect the of has cases, pathways prioritized care, various of has on and far contribution indication, in to activation, believe which risk compared treat, that anti-tumor to insight and tumor a of were hardest only and this into probability activity as microenvironment two and the COMXXX the the support the with move end, intention less but have able In One, components flexibility subsets To with to of indications reflects in two been initial independently been were indications that of success to much changes tumor type. higher a identified with We so these suggesting tumor may a occurring believe treat mediated components In of immunologically part an as decided dominance overlapping we as and with also included learn to to bar some anti-tumor types, future to tumor in action. COMXXX. colorectal
in therefore may and an the The patient to for cell treated tumor is inflamed responsive is environment DNAM although a permissive non-small cancer PD-X patients. anti more These lung second present immunologically tumor population challenging more treat. activity, axis is types
in overall for this setting patient Lonsurf, back no therapies, is this which population. patient, activity six rate of of X% combination no cancer. survival There rate X% two has Going free progression third this response typically only monotherapy line approved limited months. in Treatment median X% have an checkpoint specifically or survival shown of in to to and show pembrolizumab immune Also demonstrated [indiscernible]. population, a inhibitors of and response greater with or overall stable of months response microsatellite to improving overall seven regorafenib median in colorectal note, months is
or today, with of shown with from XX data line in anti-tumor response of have XX of As various an preliminary presented partial encouraging rate greater and across overall COMXXX third response nivolumab using including setting of without activity doses have patients we or studies X%, one we week.
this compared has reported the higher cohort a that dose been with a initial the driven what the of showing triple modestly mechanism of patients MSS-CRC in study. translational combination for data in clinical patients escalation believe data from number COMXXX COMXXX small Our study warrant expansion care. along of in COMXXX arm evaluation rate standard show further nivolumab response We to package MSC-CRC single
an an non-small as high PD-X study triplet response clinical of a exemplify population and triple tumor with plan need We of where positive high in cancer, as as lung to regulatory us checkpoint, possibly easily data first-line TIGIT and post in have focus indication a checkpoint cancer considerations, type we response arm patient lung as are to unmet lung probability to selected and described duration study population to allow an opposed our specifically inhibitors. may other the already priority non-small may patients high cell the of non-small combination single rate to patient we uniqueness PD-X Next, cell drug anti our combination. the more responding inflamed due landscape to where on cancer increased sensitive a
therefore to in this we the may combination competitive presence of activity and TIGIT to of regarding in the blockade will build plan path additional This this a axis patients allow in addition, also a DNAM insights randomized to hurdles triple separately to present to of risk study, an and due generate first-line In care in milestone. studies the and evaluate with PVRIG delay parallel In presents standard reach population. data checkpoint chemotherapy. to to setting us patient re-dose in significant reasons enrollment
stable microsatellite year. cancer data the As from previously COMXXX colorectal share communicated, we QX in cohort this the of plan to nivolumab
our efforts decision and end the strategic of plan studies and present the expansion do projection focus half to cohorts. other currently we Given the to on year prioritized data our not indications, enrollment prior cohort to from completion a early,
continuing our in be for each indications data Our respond The will We by We these in initial reported key this effective details patients of and most in focus for and XX will fourth the their on aim shared conduct existing execution experts design to once of progress have, findings studies three indication. patients we been XXXX. with up prioritized of share COMXXX this others the track on has the with studies, of during to studies expand and are plan likely protocol record to the be finalized study the quarter to arm of COMXXX discussions will these consist year. based timeline the who of enrich to plan the an plus single execution. and what
Moving on, Compugen to our core pioneers. scientists are research programs.
continue on work immune micro to the the We cells modulating in environment. tumor groundbreaking do focusing suppressive
by several capabilities advancing early computational program predicted studies discovery We all one enabling with are entering our potential. stage pre-IND with first-in-class programs
immune is developed do response checkpoint this We pathway to We the a so. are antibody, are excited first high and in this very in block we we to IFN-γ. the about believe COMXXX, very to which microenvironment soluble a upregulated targeting soluble affinity program, tumor immune checkpoint
program We combination in-vivo various across And of models. execute $XX this strong have quarter through cash. and the demonstrated on finally, and plans ended XXXX. preclinical activity and June us with as financial fourth We end of in-vitro support plan this the in monotherapy Compugen to quarter in details in to position share clinical our million allow closed This should on our operations the XX year.
second commitment while Before process to like successor. for who want I quarter I to to pass in of moment has and also to his I to the continue in a we the thank over are agreed to goals support Ari, the Compugen take the would dedication company Compugen their identifying of thank to Ari, team year. the
